Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Open Access Gateway

Alterations in Adiposity and Glucose Homeostasis in Adult Gasp-1 Overexpressing Mice

Périè L. · Parenté A. · Baraige F. · Magnol L. · Blanquet V.

Author affiliations

University of Limoges, INRA, UMR 1061, UGMA, Limoges, France

Corresponding Author

Véronique Blanquet

Université de Limoges, UMR 1061, Unité de Génétique Moléculaire Animale,

Faculté des Sciences et Techniques, 123, av. A. Thomas,Limoges Cedex (France)

Tel. +33 555457664, E-Mail veronique.blanquet@unilim.fr

Related Articles for ""

Cell Physiol Biochem 2017;44:1896–1911

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Abstract

Background/Aims: Myostatin is known as a powerful negative regulator of muscle growth playing a key role in skeletal muscle homeostasis. Recent studies revealed that myostatin-deficient mice lead to an increase of insulin sensitivity, a decrease of adiposity and a resistance to obesity, showing that myostatin can also impact on metabolism. Thus, myostatin appeared as a potential therapeutic target to treat insulin resistance. Methods: We generated transgenic mice overexpressing Gasp-1, a myostatin inhibitor. Results: Surprisingly, we found that these mice gained weight with age due to an increase in fat mass associated with ectopic fat accumulation. In addition, these mice developed an adipocyte hypertrophy, hyperglycemia, hyperinsulinemia, muscle and hepatic insulin resistance. Understanding the molecular networks controlling this insulin resistance responsiveness in overexpressing Gasp-1 mice is essential. Molecular analyses revealed a deregulation of adipokines and muscle cytokines expression, but also an increase in plasma myostatin levels. The increase in myostatin bioactivity by a positive feedback mechanism in the Tg(Gasp-1) transgenic mice could lead to this combination of phenotypes. Conclusion: Altogether, these data suggested that overexpressing Gasp-1 mice develop most of the symptoms associated with metabolic syndrome and could be a relevant model for the study of obesity or type 2 diabetes.

© 2017 The Author(s). Published by S. Karger AG, Basel


References

  1. Wakefield LM, Hill CS: Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat Rev Cancer 2013; 13: 328-341.
  2. Shi Y, Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
  3. Massague J, Blain SW, Lo RS: TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
  4. Gordon ES, Gordish Dressman HA, Hoffman EP: The genetics of muscle atrophy and growth: the impact and implications of polymorphisms in animals and humans. Int J Biochem Cell Biol 2005; 37: 2064-2074.
  5. Burks TN, Cohn RD: Role of TGF-beta signaling in inherited and acquired myopathies. Skelet Muscle 2011; 1: 19.
  6. Akhurst RJ, Hata A: Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012; 11: 790-811.
  7. Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, de Gramont A: Targeting the TGFbeta pathway for cancer therapy. Pharmacol Ther 2015; 147: 22-31.
  8. McPherron AC, Lee SJ: Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A 1997; 94: 12457-12461.
    External Resources
  9. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Menissier F, Massabanda J, Fries R, Hanset R, Georges M: A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997; 17: 71-74.
  10. Kambadur R, Sharma M, Smith TP, Bass JJ: Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 1997; 7: 910-916.
  11. Szabo G, Dallmann G, Muller G, Patthy L, Soller M, Varga L: A deletion in the myostatin gene causes the compact (Cmpt) hypermuscular mutation in mice. Mamm Genome 1998; 9: 671-672.
  12. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ: Induction of cachexia in mice by systemically administered myostatin. Science 2002; 296: 1486-1488.
  13. Reisz-Porszasz S, Bhasin S, Artaza JN, Shen R, Sinha-Hikim I, Hogue A, Fielder TJ, Gonzalez-Cadavid NF: Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 2003; 285:E876-888.
  14. Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O, McPherron AC: Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One 2009; 4:e4937.
  15. Zhang C, McFarlane C, Lokireddy S, Bonala S, Ge X, Masuda S, Gluckman PD, Sharma M, Kambadur R: Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia 2011; 54: 1491-1501.
  16. McPherron AC, Lee SJ: Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 2002; 109: 595-601.
  17. Elliott B, Renshaw D, Getting S, Mackenzie R: The central role of myostatin in skeletal muscle and whole body homeostasis. Acta Physiol (Oxf) 2012; 205: 324-340.
  18. Feldman BJ, Streeper RS, Farese RV, Jr., Yamamoto KR: Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effects. Proc Natl Acad Sci U S A 2006; 103: 15675-15680.
  19. Wilkes JJ, Lloyd DJ, Gekakis N: Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes 2009; 58: 1133-1143.
  20. Hamrick MW, Pennington C, Webb CN, Isales CM: Resistance to body fat gain in ‘double-muscled’ mice fed a high-fat diet. Int J Obes (Lond) 2006; 30: 868-870.
  21. LeBrasseur NK, Schelhorn TM, Bernardo BL, Cosgrove PG, Loria PM, Brown TA: Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci 2009; 64: 940-948.
  22. Morissette MR, Stricker JC, Rosenberg MA, Buranasombati C, Levitan EB, Mittleman MA, Rosenzweig A: Effects of myostatin deletion in aging mice. Aging Cell 2009; 8: 573-583.
  23. Tu P, Bhasin S, Hruz PW, Herbst KL, Castellani LW, Hua N, Hamilton JA, Guo W: Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice. Diabetes 2009; 58: 1739-1748.
  24. Zhao B, Wall RJ, Yang J: Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance. Biochem Biophys Res Commun 2005; 337: 248-255.
  25. Lee SJ, McPherron AC: Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A 2001; 98: 9306-9311.
  26. Lee SJ: Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One 2007; 2:e789.
  27. Monestier O, Brun C, Heu K, Passet B, Malhouroux M, Magnol L, Vilotte JL, Blanquet V: Ubiquitous Gasp1 overexpression in mice leads mainly to a hypermuscular phenotype. BMC Genomics 2012; 13: 541.
  28. Perie L, Parente A, Brun C, Magnol L, Pelissier P, Blanquet V: Enhancement of C2C12 myoblast proliferation and differentiation by GASP-2, a myostatin inhibitor. Biochem Biophys Rep 2016; 6: 39-46.
  29. Brandt C, Hansen RH, Hansen JB, Olsen CH, Galle P, Mandrup-Poulsen T, Gehl J, Pedersen BK, Hojman P: Over-expression of Follistatin-like 3 attenuates fat accumulation and improves insulin sensitivity in mice. Metabolism 2015; 64: 283-295.
  30. Gangopadhyay SS: Systemic administration of follistatin288 increases muscle mass and reduces fat accumulation in mice. Sci Rep 2013; 3: 2441.
  31. Brun C, Perie L, Baraige F, Vernus B, Bonnieu A, Blanquet V: Absence of hyperplasia in Gasp-1 overexpressing mice is dependent on myostatin up-regulation. Cell Physiol Biochem 2014; 34: 1241-1259.
  32. Magnol L, Monestier O, Vuillier-Devillers K, Wagner S, Cocquempot O, Chevallier MC, Blanquet V: A sensitised mutagenesis screen in the mouse to explore the bovine genome: study of muscle characteristics. Animal 2011; 5: 663-671.
  33. Samuel VT, Shulman GI: Mechanisms for insulin resistance: common threads and missing links. Cell 2012; 148: 852-871.
  34. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
  35. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, Chow WS, Wat NM, Xu JY, Hoo RL, Xu A: Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007; 53: 34-41.
  36. Juhan-Vague I, Alessi MC: PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
    External Resources
  37. Hill JJ, Qiu Y, Hewick RM, Wolfman NM: Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol 2003; 17: 1144-1154.
  38. Tamura Y, Kawao N, Yano M, Okada K, Matsuo O, Kaji H: Plasminogen activator inhibitor-1 deficiency ameliorates insulin resistance and hyperlipidemia but not bone loss in obese female mice. Endocrinology 2014; 155: 1708-1717.
  39. Hadad N, Burgazliev O, Elgazar-Carmon V, Solomonov Y, Wueest S, Item F, Konrad D, Rudich A, Levy R: Induction of cytosolic phospholipase a2alpha is required for adipose neutrophil infiltration and hepatic insulin resistance early in the course of high-fat feeding. Diabetes 2013; 62: 3053-3063.
  40. Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, He M, Juguilon H, Yin YQ, Phillips CT, Yu RT, Olefsky JM, Henry RR, Downes M, Evans RM: A PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 2012; 485: 391-394.
  41. Tanigaki K, Vongpatanasin W, Barrera JA, Atochin DN, Huang PL, Bonvini E, Shaul PW, Mineo C: C-reactive protein causes insulin resistance in mice through Fcgamma receptor IIB-mediated inhibition of skeletal muscle glucose delivery. Diabetes 2013; 62: 721-731.
  42. Araujo TG, Oliveira AG, Carvalho BM, Guadagnini D, Protzek AO, Carvalheira JB, Boschero AC, Saad MJ: Hepatocyte growth factor plays a key role in insulin resistance-associated compensatory mechanisms. Endocrinology 2012; 153: 5760-5769.
  43. Meissburger B, Stachorski L, Roder E, Rudofsky G, Wolfrum C: Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans. Diabetologia 2011; 54: 1468-1479.
  44. Hittel DS, Axelson M, Sarna N, Shearer J, Huffman KM, Kraus WE: Myostatin decreases with aerobic exercise and associates with insulin resistance. Med Sci Sports Exerc 2010; 42: 2023-2029.
  45. Takahashi H, Sato K, Yamaguchi T, Miyake M, Watanabe H, Nagasawa Y, Kitagawa E, Terada S, Urakawa M, Rose MT, McMahon CD, Watanabe K, Ohwada S, Gotoh T, Aso H: Myostatin alters glucose transporter-4 (GLUT4) expression in bovine skeletal muscles and myoblasts isolated from double-muscled (DM) and normal-muscled (NM) Japanese shorthorn cattle. Domest Anim Endocrinol 2014; 48: 62-68.
  46. Mann N, Rosenzweig A: Can exercise teach us how to treat heart disease? Circulation 2012; 126: 2625-2635.
  47. Dong J, Dong Y, Dong Y, Chen F, Mitch WE, Zhang L: Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues. Int J Obes (Lond) 2016; 40: 434-442.
  48. Shan T, Liang X, Bi P, Kuang S: Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1alpha-Fndc5 pathway in muscle. FASEB J 2013; 27: 1981-1989.
  49. Lin J, Arnold HB, Della-Fera MA, Azain MJ, Hartzell DL, Baile CA: Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem Biophys Res Commun 2002; 291: 701-706.
  50. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi PA: Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 2003; 17: 2299-2301.
  51. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM: Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004; 2:e294.
  52. Artaza JN, Singh R, Ferrini MG, Braga M, Tsao J, Gonzalez-Cadavid NF: Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiation into myofibroblasts. J Endocrinol 2008; 196: 235-249.
  53. Bouzakri K, Plomgaard P, Berney T, Donath MY, Pedersen BK, Halban PA: Bimodal effect on pancreatic beta-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes 2011; 60: 1111-1121.
  54. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK, Colvin RA, Kihara S, Funahashi T, Luster AD, Libby P: Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 2008; 102: 218-225.
  55. Harmon EB, Apelqvist AA, Smart NG, Gu X, Osborne DH, Kim SK: GDF11 modulates NGN3+ islet progenitor cell number and promotes beta-cell differentiation in pancreas development. Development 2004; 131: 6163-6174.
  56. Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW: HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 2003; 52: 1695-1700.
    External Resources
  57. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, Bogner JR, Landgraf R, Goebel FD: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12:F167-173.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: July 04, 2017
Accepted: November 01, 2017
Published online: December 08, 2017
Issue release date: Published online first (Issue-in-Progress)

Number of Print Pages: 16
Number of Figures: 9
Number of Tables: 2

ISSN: 1015-8987 (Print)
eISSN: 1421-9778 (Online)

For additional information: https://www.karger.com/CPB


Open Access License / Drug Dosage / Disclaimer

This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.